WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 3'4401 Infant (under 12 months) mortality rate: 262
GDP / capita (US$): 7'5271 Child (under 5 years) mortality rate: 322

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 15'860  15'468  15'083  14'707  14'342  11'204  8'890  7'001 
Births 486  480  474  469  463  412  349  302 
Surviving infants 475  469  463  457  451  395  328  276 
Pop. less than 5 years 2'287  2'250  2'215  2'184  2'161  1'859  1'517  1'262 
Pop. less than 15 years 6'354  6'254  6'151  6'050  5'955  4'937  4'034  3'177 
Female 15-49 years 3'992  3'875  3'760  3'647  3'534  2'621  1'952  1'545 

Number of reported case

(Click for retrospective incidence data for Guatemala)
Diphtheria
Japanese encephalitis
Measles 8'802  2'703 
Mumps 143 
Pertussis 25  34  273  146  130  1'513 
Polio* 287 
Rubella 276 
Rubella (CRS)
Tetanus (neonatal) 60 
Tetanus (total)** 11  60  60 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Guatemala)
Vaccine year result method % card seen                                                
BCG 2007  97  MCH   87  91  97  94  91  99*  95  62  36 
DTP1 2007  96  MCH   87  89  99*  99*  94  97  94 
DTP3 2007  84  MCH   87  73  93  96  88  94  95  66  43 
DTP4          56 
IPV1         
HepB_BD          22  37  35  31  15 
HepB3          73  93  96  88  94 
Hib3          73  93  96  88  94 
JapEnc         
MCV1          67  93  93  89  93  86  68  23 
MCV2          59 
PCV1          78  88 
PCV3          51  24 
Pol3 2007  85  MCH   87  65  92  94  88  94  93  74  43 
Rota1          65  99*  99*  81  30 
Rota_last          54  88  81  71  38 
Rubella1          67  93  93  89  93 
TT2plus 2001  49  MCH   69  99*  99*  99*  22  27 
PAB         
VAD1          64  46  34  63  82  49 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Guatemala)
BCG 91  88  94  91  99  95  62  36 
DTP1 89  97  96  94  96  94  86  68 
DTP3 73  85  96  88  94  81  66  43 
HepB3 73  85  96  88  94 
HepB_BD 22  32  35  31  15 
Hib3 73  85  96  85  94 
MCV1 67  85  93  89  93  86  68  23 
MCV2
PAB 85  85  85  85  85  67  44 
PCV3 51  24 
Pol3 65  84  94  88  94  80  74  43 
Rota_last 54  81  81  71  38 

Number of districts in the country 334  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 26
From 80 to 89% 15
From 50 to 79% 49
Less than 50% 10
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG < 1 year; Yes
DTwP 18 months; 4 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepB_Adult st contact; +4 weeks; +6 months; Yes
HepB_Pediatric birth; Yes
Influenza_Adult Yes Elderly, pregnant women, health care workers and risk groups
MMR 12-23 months; Yes
OPV 2, 4, 6, 18 months; 4 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Rotavirus 2, 4 months; Yes
Td 1st contact; +4 weeks; +6 months; +1, +1 year; Yes or 1st contact; +4 weeks; +6 months; +10, +10 years (if not at risk)
VitaminA 6-59, 12-59 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  Yes  No  Yes  No  No 
What years does the MYP cover? number     2012-2016    2011-2015     
Nº of districts with microplans that include activities to raise immunization coverage number   334    335  332  333  332 

System performance

Total Nº districts in country number 334  334  334  335  332  333  332 
Nº districts with DTP3 coverage >=80% number 136  249  305  256  266  263  312 
% of districts with DTP3 coverage >=80% From 0 to 100% 41  75  91  76  80  79  94 
Nº districts with measles (MCV1) coverage >=95% number 47  141  130  71  179  162  231 
% of districts with MCV1 coverage >=95% From 0 to 100% 14  42  39  21  54  49  70 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND no  No  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 99  100  99  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  No  No  No     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.